Novartis joins forces with Allergan, pushing a NASH combo into late-stage development
Looking to leapfrog some intense competition to field new drugs for NASH and fatty liver disease, pharma giant Novartis has struck a deal to partner with Allergan on a new combo approach that will start out in a Phase IIb trial.
Novartis is combining an FXR agonist with Allergan’s cenicriviroc — CVC — for the treatment of non-alcoholic steatohepatitis. And they’re keeping the numbers side of the arrangement under wraps.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.